Reducing a major cost burden of therapeutic cell manufacturing by selectivelyremoving toxic culture byproducts to allow recycling of media
Ended Project Grant Awarded Last action
- Award ID
- R41GM140787
- Recipient
-
Ossium Health, Inc. UEI FFNHJ2RDRHW3
- Awarding agency
-
National Institute of General Medical Sciences
National Institutes of Health, Department of Health and Human Services
- Obligated
- $562,007
Award facts
- Assistance listing
- 93.859 Biomedical Research and Research Training
- Completion date
- Funding
-
- $337,554.49 Federal
- $224,453.00 Non-federal
- Place of performance
- Indianapolis, IN 46202, USA
Award details come from USAspending.gov.
Description
- Abstract
- The tremendous cost of cell-based therapies manufacturing is the significant threat to the success of cell/gene therapy treatments. The cell culture medium alone can contribute to around 30-40% of the cost of goods (COGS). This is because, the current cell culture methods require frequent and complete media replacement in order to remove toxic metabolites from culture. This practice of completely replacing the medium with fresh medium adds significant expense and contributes to unnecessary waste. Restoring nutrient, osmotic, and PH balance need not require replacement of the entire culture medium volume. At production scale, some version of medium recycling will be required to reduce waste and overall cost of manufacturing. The aim of the current study is to develop a cost-effective media filtration system using coconut-shell derived activated carbons (CS-AC) that can selectively remove two important toxic metabolites such as lactic acid and ammonium from cell culture medium. With such filtration system, metabolic waste products can selectively be removed, non- metabolized components like buffers, and growth factors can be retained, and the depleted nutrients like sugars and amino acids can be replenished as they are consumed by the cells. Determining the level of recycling that is achievable by this filtration technology for each component of the culture medium requires a significantly more complex analysis informed by empirical data from spent medium analysis. The ultimate goal of this study is to utilize this filtration technology and develop a commercial grade single-use filtration device by embedding the AC into cellulose matrix or neutral-grade resins. The application of the new filtration device to remove toxic metabolites from spent culture medium will transform the current approaches being investigated for COG reduction during cell based therapeutic manufacturing. Such a filtration system holds a great promise for affordable cell/gene therapy treatment possibilities, and is expected to have a strong economical impact on clinical medicine.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | -$111,352 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $224,453 | $0 | |
| Original award | $224,453 | $224,453 |
Quick answers
Who received award R41GM140787?
R41GM140787 was awarded to Ossium Health, Inc. by National Institute of General Medical Sciences (National Institutes of Health) on September 20, 2021.
How much is award R41GM140787 worth?
$562,007 has been obligated on R41GM140787: $337,554 in federal funding and $224,453 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award